Lv11
22 积分 2023-09-27 加入
First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases
55分钟前
待确认
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
1小时前
已完结
Comparing the effectiveness and safety of first-line interventions in patients with advanced epidermal growth factor receptor-mutant non-small cell lung cancer, with particular focus on brain metastatic status: a systematic review and network meta-analysis
1小时前
已完结
Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
2天前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
2天前
已完结
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer
2天前
已完结
1550TiP Phase II, multicenter, randomized, open-label study of DS-7300 in patients (pts) with pre-treated extensive-stage small cell lung cancer (ES-SCLC)
9个月前
已完结
P2.16-06 A Phase 2 Study of Ifinatamab Deruxtecan (I-DXd; DS-7300) in Patients with Previously Treated ES-SCLC
9个月前
已完结
IDeate-Lung02: A phase 3, randomized, open-label study of ifinatamab deruxtecan (I-DXd) vs treatment of physician’s choice (TPC) in relapsed small cell lung cancer (SCLC)
9个月前
已完结
OA04.03 Ifinatamab Deruxtecan (I-DXd) in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Interim Analysis of Ideate-lung01
9个月前
已完结
皖公网安备34019202002308
